ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Earnings for ImmunityBio, Inc. (IBRX)
Earnings in 2023 (TTM): $-583,892,000
According to ImmunityBio, Inc.'s latest financial reports the company's current earnings (TTM) are $-583,892,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of ImmunityBio, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-583,892,000 | $-583,196,000 |
| 2022 | $-417,286,000 | $-417,320,000 |
| 2021 | $-349,839,000 | $-349,848,000 |
| 2020 | $-226,033,000 | $-224,187,000 |
| 2019 | $-160,263,000 | $-160,158,000 |
| 2018 | $-96,729,000 | $-96,226,000 |
| 2017 | $-96,916,000 | $-96,423,000 |
| 2016 | $-121,381,000 | $-120,809,000 |
| 2015 | $-237,177,000 | $-236,876,000 |
| 2014 | $-6,212,000 | $-6,213,000 |
| 2013 | $-2,045,999 | $-2,047,000 |